Biomarker-Based Platform for Early Diagnosis of Chronic Liver Disease to Enable Personalized Therapy (LIVERAIM)

肝硬变和肝癌很常见，是高发病率、生活质量受损、医疗保健系统的主要成本，在欧洲每年导致30万人死亡。主要的致病因素是肥胖、2型糖尿病和饮酒量增加，这些都在上升。据预测，由于死于肝病，未来30年欧洲人的健康预期寿命将会减少。无症状的肝纤维化经过很长一段时间后才会发展成肝硬变，直到患者因肝硬变或肝癌而出现严重并发症时才会被发现。目前唯一有效的治疗方法是肝移植，但这并不适用于所有患者。如果及早发现纤维化，以确定肝病的病程，那么肝纤维化是可逆的。LIVERAIM项目汇集了一支由知名临床中心和工业合作伙伴组成的团队，包括中小企业，他们在肝病领域拥有丰富的专业知识，目的是设计和验证一个带有生物标记物的筛查平台，用于整个欧洲的人口筛查。其目的是及早识别肝病并应用个体化治疗干预。大量现有的生物标记物将使用来自之前欧盟资助的H2020队列的40,000名受试者的生物库血浆样本来测试纤维化预测的准确性。LIVERAIM将开发一个带有使用人工智能的生物标记物的筛查平台，用于个性化的纤维化早期诊断，并在来自6个具有代表性的欧盟国家的10万名受试者的随机对照试验中进行验证。该平台将链接到量身定做的个性化治疗干预措施，以阻止纤维化进展。通过LIVERAIM，早期诊断和个性化干预可以阻止肝病的发展，有助于降低发病率和死亡率以及相关的社会负担，包括经济和卫生不平等

Liver cirrhosis and liver cancer are common and responsible for high morbidity, impaired quality of life, major costs for healthcare systems, causing 300K deaths per year in Europe. Predominant etiological factors are obesity, type2 diabetes, and increased alcohol in take, which are all on the rise. It is predicted that healthy life expectancy will decrease in Europe over the next 30 years because of deaths due to liver disease. Liver cirrhosis develops after a very long period of asymptomatic liver fibrosis, staying undetected until patients develop severe complications due to cirrhosis or liver cancer. Currently the only effective treatment available is liver transplantation which is not applicable to all patients. If fibrosis is detected early, to target the course of liver disease, then liver fibrosis is reversible. The LIVERAIM project concentrates a team of renowned clinical centres and Industrial partners, including SMEs, with great expertise in the field of Liver Disease, the aim being to design and validate a screening platform with biomarkers for population screening to use across Europe. The objective isto identify liver disease early and apply personalized therapeutic interventions. A large number of existing biomarkers will be tested for fibrosis prediction accuracy using biobank plasma samples from 40,000 subjects from previous H2020 EU funded cohorts. LIVERAIM will develop a screening platform with biomarkers using AI for personalized early diagnosis of fibrosis to be validated in a RCT of 100K subjects from 6 representative EU countries. The platform will be linked to tailored, personalized therapeutic interventions to halt fibrosis progression. With LIVERAIM, early diagnosis and personalized intervention can stop liver disease progression, help decrease morbidity and mortality and the associated societal burdens both economic and health inequity